How Do Different Weight Loss Injections Compare in Terms of Dosage, Duration and Cost in 2026?
Weight loss injections continue to attract attention in 2026, with treatment plans often lasting from 3 to 12 months or longer depending on individual goals. Many programs use weekly injections, while some follow different dosing schedules. Typical starting doses may increase gradually over several weeks, and weight changes are often tracked monthly. Factors such as body weight, BMI, treatment duration and medication type can all influence the overall experience and outcomes.
Prescription injectable treatments for weight management have grown significantly in availability across the United Kingdom. From weekly self-administered pens to clinician-supervised programmes, the landscape is more varied than ever. Knowing how these treatments compare on a practical level, including how much they cost, how long they take to work, and how dosages are structured, can help patients ask the right questions before committing to a programme.
This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalised guidance and treatment.
Comparison of Popular Injectable Slimming Brands
Several injectable treatments are currently used in weight management programmes in the UK. Semaglutide, sold under brand names such as Ozempic and Wegovy, is a GLP-1 receptor agonist originally developed for type 2 diabetes but now licensed for weight management. Liraglutide, marketed as Saxenda, is an older GLP-1 medication administered daily rather than weekly. Tirzepatide, available as Mounjaro, is a dual GIP and GLP-1 receptor agonist that has gained attention for its clinical outcomes. Each of these works differently at a hormonal level, and their suitability varies depending on a person’s health profile.
Body Weight and Dosage Comparison Chart
Dosage structures vary considerably across these treatments. Semaglutide (Wegovy) typically starts at 0.25mg weekly and is gradually increased over several months to a maintenance dose of 2.4mg. Liraglutide (Saxenda) begins at 0.6mg daily and increases in weekly steps up to 3mg daily. Tirzepatide (Mounjaro) starts at 2.5mg weekly and can be titrated up to 15mg weekly depending on tolerability and clinical response. These dose escalation schedules are designed to minimise side effects such as nausea, and they mean the early weeks of treatment involve lower doses than the eventual maintenance phase. Body weight can influence the prescribing decision, though individual clinical assessments remain the standard approach.
Monthly Treatment Schedules and Usage Frequency
The frequency of administration is a meaningful practical factor. Weekly injections, as used with Wegovy and Mounjaro, tend to suit people who prefer less frequent dosing and can manage a consistent weekly schedule. Saxenda requires daily injections, which some patients find more manageable in terms of routine, while others find it a higher burden. Most structured programmes in the UK run for a minimum of 12 weeks before any clinical review of progress, with full programmes often spanning 6 to 12 months or longer. Treatment is generally continued only while the benefits are maintained and the medication is well tolerated.
Comparison of Weight Management Programmes by Duration
Weight management programmes in the UK vary widely in structure and duration. Some are delivered entirely online through registered digital clinics, while others involve in-person consultations with GPs or specialist obesity services. NHS access to these treatments remains limited and is typically prioritised for patients with specific clinical criteria, including a BMI above a set threshold and associated health conditions. Private programmes can begin more quickly but carry a cost. The duration of a programme also affects the total investment required, as monthly prescription costs accumulate over time.
Price Comparison Table of Injectable Slimming Treatments
Private prescription costs for these treatments in the UK vary by provider, medication, and whether the cost includes consultations. The figures below represent general market estimates as of 2026 and are intended as a guide only.
| Medication | Brand Name | Typical Monthly Cost (UK Private) | Administration Frequency |
|---|---|---|---|
| Semaglutide | Wegovy | £150 – £300 | Weekly |
| Semaglutide | Ozempic (off-label use) | £80 – £180 | Weekly |
| Liraglutide | Saxenda | £180 – £250 | Daily |
| Tirzepatide | Mounjaro | £150 – £280 | Weekly |
Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.
What to Consider Before Starting a Programme
Beyond cost, several factors matter when evaluating injectable weight management options. These include the prescriber’s qualifications, whether ongoing monitoring is included, how side effects are managed, and what happens if the treatment needs to be stopped. The Medicines and Healthcare products Regulatory Agency (MHRA) and NHS guidance both advise that these treatments should only be used under medical supervision. Patients should be wary of unregistered online suppliers, as counterfeit or incorrectly stored products have been reported in the UK market.
Comparing injectable weight management treatments involves weighing up more than just price. Dosage complexity, the frequency of administration, programme length, and the level of clinical oversight all play a role in determining which option might be most appropriate for any given individual. Consulting a registered healthcare professional remains the most reliable starting point before beginning any weight management treatment.
